Comparison of older and newer neuroleptics for the treatment of schizophrenia

References

• Chinchilla A. Gm-a terapéutica de las esquizofienias. Masson S. A., Barcelona (2000).
   Google Scholar
• Kane DA, Honigfeld G, Singer J et al
   Google Scholar
• ••Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine ibenztropine. Azrh. Gen Psychiatry45(9), 789–796 (1988).
   Google Scholar
• Meltzer HY, Bastani B, Kwon KY et al. A
   Google Scholar
• •prospective study of clozapine in treatmentresistant schizophrenic patients. I. Preliminary report. Psychopharmacology Berl 99(Suppl.), S68—S72 (1989).
   Google Scholar
• Lindenmayer JP, Grochowski S, Mabugat L. Clozapine events on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. j Clin. PFhopharmacol 14(3), 201–204 (1994).
   Google Scholar
• Breier A, Buchanan RW, Kirkpatrick B
   Google Scholar
• •et al Events of clozapine on positive and negative symptoms in out-patients with schizophrenia. Am. J. PFchiatry151(1), 20–26 (1994).
   Google Scholar
• McElroy SL, Dessain EC, Pope HG Jr. et al Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. J. an. PFhiatry52(10), 411–414 (1991).
   Google Scholar
• Banov MD, Zarate CA Jr., Tohen M et al Clozapine therapy in refractory affective disorders: polarity predicts rsponse in long-term follow-up. J. Clin. Psychiatry 55(7), 295–300 (1994).
   Google Scholar
• Naber D, Hippius H. The European experience with the use of clozapine. Hasp. Community fiychiatry41(8), 886–890 (1990).
   PubMedGoogle Scholar
• Meltzer HY, McGurk SR. The effects of
   Google Scholar
• ••clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25(2), 233–255 (1999).
   Google Scholar
• Hamilton SH, Edgell ET, Revicki DA et al.
   Google Scholar
• •Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European Sample. Int. Clin. Psychopharmacol. 15, 245–255 (2000).
   Google Scholar
• Sanger TM, Lieberman JA, Tohen M et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156(1), 79–87 (1999).
   Google Scholar
• Dellva MA, Tran PV, Tollefson GD et al Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 48(12), 1571–1577 (1997).
   PubMed Web of Science ®Google Scholar
• Tran PV, Dellva MA, Tollefson GD et al.
   Google Scholar
• •Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. BE J. Psychiatry 172,499-505 (1998).
   Google Scholar
• Beasley CM Jr., Sanger T, Satterlee W et al Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. PFhophalmacology Berl. 124(1-2), 159–167 (1996).
   Google Scholar
• Beasley CM Jr., Tollefson G, Tran P et al Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14(2), 111–123 (1996).
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM, Tran PV et al.
   Google Scholar
• •Olanzapine versushaloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an internatonal collaborative trial. Am J. Psychiatry154(4), 457–465 (1997).
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ et al.
   Google Scholar
• •Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. fiychopharmacol 17(5), 407–418 (1997).
   Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Arm PFlziatry158(5), 765–774 (2001).
   Google Scholar
• Tollefson GD, Sanger TM, Lu Y et al
   Google Scholar
• •Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Ann Gen P Fchiatry55(3), 250–258 (1998).
   Google Scholar
• Tran PV, Tollefson GD, Sanger TM et al Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. BE j PFchiatry174, 15–22 (1999).
   Google Scholar
• Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr. Res. 35, S13–S21 (1999).
   Google Scholar
• Purdon SE, Jones BDW, Stip E et al
   Google Scholar
• ••Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Rychiatry57 (3), 249–258 (2000).
   Google Scholar
• Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 48(1), 17–28 (2001).
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of `Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. fiychiatry 42 (4), 233–246 (1997) .
   Google Scholar
• Wirshing DA, Wirshing WC, Marder SR et al New antipsychotics: a practical review. Medscape Ment. Health 2 (1997).
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA et al
   Google Scholar
• •Quetiapine in patients with schizophrenia: a high and low dose double-blind dose comparison with placebo. Arch. Gen fiychiatry 54(6), 549–557 (1997).
   Google Scholar
• Arvanitis LA, Miller BG, Kowalcyk BB et al Efficacy of `Seroquel' (quetiapine fumerate) in affective symptoms of schizophrenia. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology Honolulu, Hawaii, USA (1997).
   Google Scholar
• Marder SR, Meibach RC. Risperidone in
   Google Scholar
• •the treatment of schizophrenia. Am. J. Psychiatry 151(6), 825–835 (1994).
   Google Scholar
• Bondolfi G, Dufour H, Patris M et al Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J. Psychiatry 155(4), 499–504 (1998).
   Google Scholar
• Ames D, Wirshing WC, Marshall BD et al. Treatment-resistant schizophrenia: evaluation of risperidone versushaloperidol. 52nd Annual Annual Convention of the society of biological psychiatry San Diego, California, USA (1997).
   Google Scholar
• Chouinard G, Jones B, Remington G et al. A canadian multicentre placebo-controled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. j Clin. fiychopharmacol 13(1), 25–40 (1993).
   PubMed Web of Science ®Google Scholar
• Peuskens J. Risperidone in the treatment of
   Google Scholar
• •patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone study group. BE J. Psychiatry 166(6), 712–726 (1995).
   Google Scholar
• Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms in schizophrenia: a meta-analysis. Int. Clin. fiychopharmacol 10(4), 207–213 (1995).
   Google Scholar
• Muller-Seicheneder F, Muller MJ, Hillert A et al Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J. Clin. PTchopharmacol 18(2), 111–120 (1998).
   Google Scholar
• Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry26(4), 121–124 (1993).
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG et al
   Google Scholar
• •Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20(5), 491–505 (1999).
   Google Scholar
• Arató M, O'Connor R, Meltzer H et al. Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. Eur NeuropTchopharmacol 7\(Suppl. 2), S214 (1997).
   Google Scholar
• O'Connor R, Harrigan EP, Heym J et al The efficacy and safety profile of a new antipsychotic, ziprasidone. Xth World Congtess of Psychiatry Madrid, Spain (1996).
   Google Scholar
• Harrigan E, Morrisey M. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder. 149th Annual Meeting of the American fiychiatric Association. New York City, USA (1996).
   Google Scholar
• Keck PE Jr., Harrigan EP, Reeves KR. The efficacy of ziprasidone in schizophrenia and schizoaffective disorder: an update. Biol. fiychiatry 42 (Suppl.), 42S (1997) .
   Google Scholar
• Street JS, Tamura R, Sanger T et al. Long- term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. 36th Annual NCDEU Meeting Boca Raton, Florida, USA (1996).
   Google Scholar
• David SR, Taylor CC, Kinon BJ et al The effects of olanzapine, risperidone and haloperidol on plasmatic prolactin levels in patients with schizophrenia. Clin. The: 22(9), 1085–1096 (2000).
   Google Scholar
• Goren JL, Levin GM. Quetiapine, a new antipsychotic. Pharmacotherapy 18 (6), 1183–1194 (1998).
   PubMed Web of Science ®Google Scholar
• Reeves KR, Harrigan EP Efficacy and safety of ziprasidone: an update. 35th Annual Meeting of the American College of Neumpsychopharmacology (1996).
   Google Scholar
• Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2, CD001945 (2000).
   Google Scholar
• Gury C, Canceil 0, Iaria P Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26(6), 62–72 (2000).
   Google Scholar
• World Health Organization. The constitution of the 14brIcl I-kalth Organization. WHO Chronicle. 6–24 (1947).
   Google Scholar
• Lamb RH. The new asylums in the community. Arch. Gen. Psychiatry 36 (2), 129–134 (1979).
   Google Scholar
• Awad AG, Voruganti LNP, Heslegrave RJ.
   Google Scholar
• •Measuring quality of life in patients with schizophrenia. Pharmacoeconomics11(1), 32–47 (1997).
   Google Scholar
• Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am. fiychiatry139,1271–1276 (1982).
   Google Scholar
• Lehman AF The well-being of chronic mental. Arch. Gen. PTchiatr 40(4), 369–373 (1983).
   PubMedGoogle Scholar
• McDowell I, Newell C. Measuring- Health: A guide to Rating Scales and Questionnahes (2ncl al). Oxford University Press, New York, USA (1996).
   Google Scholar
• Bergner M, Bobbit RA, Carter WB et al The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19(8), 787–805 (1981).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr., Lu R et al The MOS 36-item Short-Form health survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Med. Care 32(1), 40–66 (1994).
   Google Scholar
• Kind P.The EuroQoL Instrument: an index of HRQOL. In: Quality of life and pharmacoeconomics in clinical trials (2nd ech) B. Spilker B (Ed.), Lippincott-Raven, Philadelphia, USA 191–201 (1996).
   Google Scholar
• Gaite,L, Vazquez-Barquero JL, Arrizabalaga A et al. Quality of life in schizophrenia: development, reliability and internal consistency of the Lancashire Quality of Life Profile-European Version. EPSILON Study 8. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br Psychiatry39(Suppl.), s49—s54 (2000).
   Google Scholar
• Wilkinson GS, Hesdon B, Wild D et al. Self-report quality of life measure for people with schizophrenia: the SQLS. BE j Psychiatry 177,42–46 (2000).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 6(1), 21–26 (1997).
   PubMed Web of Science ®Google Scholar
• Naber D, Walther A, Kirshere T et al.
   Google Scholar
• •Subjective events of neuroleptics predict compliance. In:Prediction of neumlEptic treatment oukoliE in schizopl ffunia: concepts and methods Gaebel W Awad AG (eds.) Springer Verlag, Vienna, Austria 111–122 (1995).
   Google Scholar
• Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J. Psychiatry Neumsci. 22(4), 256–266 (1997).
   Google Scholar
• Foster RH, Goa KL. Risperidone. A harmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 14 (1), 97–133 (1998).
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Engelhart L, 011endorf D et al The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. j Gun. Psychiatry 60 (Suppl. 3), 42–47 (1999).
   Google Scholar
• Bobes J, Gutierrez M, Gibert J et al [Quality of life and disability in chronic schizofrenics treated with risperidone and previously treated with depot neurolepticsl. Actas Esp. Psiquiatr 27(4), 229–234 (1999).
   Google Scholar
• Tunis SL, Johnstone BM, Gibson PJ et al Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment in schizophrenia. j Clin. Ptychiatry60 (19), 38–45 (1999).
   PubMedGoogle Scholar
• Revicki DA, Genduso LA, Hamilton SH et al Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 8(5), 417–426 (1999).
   Google Scholar
• Awad AG, Voruganti LNP Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int. J. Soc. Psychiatty 45(4), 268–275 (1999).
   Google Scholar
• Hamilton SH, Revicki DA, Edgell ET et al Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 15(5), 469–480 (1999).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L et al
   Google Scholar
• •Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side event profile and impact on quality of life. Schizophr Res. 43(2–3), 135–145 (2000).
   Google Scholar
• Gilbody SM, Bagnall AM, Duggan L et al. Risperidone versus other new antipsychotic medication for schizophrenia. Cochrane Database Systematic Review 3, CD002306 (2000).
   Google Scholar
• Glazer WM. Formulary decisions and health economics. J. Gun. Psychiatry 59(19), 23–29 (1998).
   Google Scholar
• Buckley PE Treatment of schizophrenia: let's talk dollars and sense. Am. J. Managed Care 4(3), 369–383 (1998).
   Google Scholar
• Hamilton SH, Revicki DA, Edgell ET et al
   Google Scholar
• •Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results of an international collaborative trial. Pharmacoeconomics 15, 469–480 (1999).
   Google Scholar